索拉非尼在急性髓系白血病中的应用
Therapeutic application of sorafenib in acute myeloid leukemia
张钰 1姚足容 1余国攀1
作者信息
- 1. 南方医科大学南方医院血液科(广州,510515)
- 折叠
摘要
随着多种靶向药物的问世,急性髓系白血病(acute myeloid leukemia,AML)逐渐进入靶向治疗时代.其中索拉非尼作为一种以靶向FLT3-ITD为主的多激酶抑制剂,在AML治疗中得到广泛应用,主要用于FLT3-ITD+AML的治疗,特别是移植后的维持治疗.另外,鉴于索拉非尼的多激酶抑制特征,也有不少研究尝试将其用于FLT3野生组AML的治疗.本文综述了索拉非尼在AML中的治疗应用及相关研究进展.
Abstract
With the emergence of a variety of targeted drugs,acute myeloid leukemia(AML)has gradually entered an era of targeted therapy.As a multikinase inhibitor,mainly targeting FLT3-ITD,sorafenib is widely used in the treatment of AML,and it is mainly used for FLT3-ITD mutated AML,especially for the maintenance therapy after allogeneic hematopoietic stem cell transplantation.Besides,based on its multikinase inhibition,man-y studies have also tried to use sorafenib for the treatment of AML with FLT3-WT.Therefore,this review sum-marizes the therapeutic application and the progress of sorafenib in AML with FLT3-ITD mutation or FLT3-WT.
关键词
急性髓系白血病/索拉非尼Key words
acute myeloid leukemia/sorafenib引用本文复制引用
基金项目
国家重点研发计划(2021YFC2500300)
国家重点研发计划(2021YFC2500302)
出版年
2024
NETL
NSTL
万方数据